Jagsonpal Common Stock Shares Outstanding vs Cash And Short Term Investments Analysis

JAGSNPHARM

636.65 9.80 1.52%

Jagsonpal Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Jagsonpal Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jagsonpal Pharmaceuticals is a good investment. Please check the relationship between Jagsonpal Pharmaceuticals Common Stock Shares Outstanding and its Cash And Short Term Investments accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Common Stock Shares Outstanding vs Cash And Short Term Investments

Common Stock Shares Outstanding vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jagsonpal Pharmaceuticals Common Stock Shares Outstanding account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong relationship.

The correlation between Jagsonpal Pharmaceuticals' Common Stock Shares Outstanding and Cash And Short Term Investments is 0.66. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Jagsonpal Pharmaceuticals Limited, assuming nothing else is changed. The correlation between historical values of Jagsonpal Pharmaceuticals' Common Stock Shares Outstanding and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Jagsonpal Pharmaceuticals Limited are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Common Stock Shares Outstanding i.e., Jagsonpal Pharmaceuticals' Common Stock Shares Outstanding and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.66

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Jagsonpal Pharmaceuticals balance sheet. This account contains Jagsonpal Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Jagsonpal Pharmaceuticals Limited fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from Jagsonpal Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jagsonpal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

The Jagsonpal Pharmaceuticals' current Selling General Administrative is estimated to increase to about 72.9 M, while Tax Provision is projected to decrease to under 38.7 M.

	2021	2022	2023	2024 (projected)
Interest Expense	2.6M	4.1M	8.1M	7.7M
Depreciation And Amortization	15.3M	11.8M	16.6M	14.6M

Interest Expense Depreciation And Amortization

Jagsonpal Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Current Deferred Revenue	Good Will	Other Liab
Total Assets		-0.23	0.34	-0.07	0.91	-0.33	-0.08	0.78	-0.1	-0.37	0.07	0.77	-0.47	0.2	-0.14	-0.78	0.51	-0.06	-0.22	0.9	-0.31	0.17	0.09	-0.31	-0.78	-0.29
Short Long Term Debt Total	-0.23		-0.62	0.55	-0.58	0.87	0.9	-0.44	-0.57	0.61	0.27	-0.49	0.82	-0.08	0.34	0.12	-0.43	-0.2	0.94	-0.47	0.94	-0.07	-0.61	-0.25	0.3	0.72
Other Current Liab	0.34	-0.62		0.11	0.5	-0.42	-0.57	0.47	0.42	-0.31	-0.24	0.4	-0.46	0.05	-0.74	-0.17	0.32	0.05	-0.51	0.4	-0.45	0.05	0.32	0.36	-0.33	-0.55
Total Current Liabilities	-0.07	0.55	0.11		-0.35	0.67	0.34	-0.18	-0.04	0.69	0.18	-0.38	0.49	-0.07	-0.56	0.16	-0.29	-0.32	0.69	-0.41	0.7	-0.05	0.03	-0.07	0.36	0.29
Total Stockholder Equity	0.91	-0.58	0.5	-0.35		-0.63	-0.39	0.79	0.08	-0.59	-0.02	0.82	-0.69	0.16	-0.2	-0.67	0.58	0.03	-0.59	0.96	-0.63	0.12	0.24	-0.18	-0.77	-0.48
Property Plant And Equipment Net	-0.33	0.87	-0.42	0.67	-0.63		0.74	-0.65	-0.42	0.86	0.17	-0.72	0.89	-0.42	0.09	0.22	-0.68	-0.13	0.93	-0.58	0.95	-0.41	-0.46	0.04	0.55	0.79
Net Debt	-0.08	0.9	-0.57	0.34	-0.39	0.74		-0.3	-0.87	0.39	0.36	-0.33	0.78	-0.03	0.41	0.1	-0.39	-0.16	0.75	-0.26	0.8	-0.02	-0.81	-0.39	0.05	0.81
Retained Earnings	0.78	-0.44	0.47	-0.18	0.79	-0.65	-0.3		0.07	-0.65	0.02	0.91	-0.68	0.58	-0.2	-0.64	0.69	-0.09	-0.49	0.76	-0.56	0.56	0.23	-0.38	-0.85	-0.57
Cash	-0.1	-0.57	0.42	-0.04	0.08	-0.42	-0.87	0.07		-0.09	-0.38	0.09	-0.54	-0.03	-0.38	-0.04	0.27	0.11	-0.37	-0.02	-0.45	-0.03	0.79	0.52	0.22	-0.75
Non Current Assets Total	-0.37	0.61	-0.31	0.69	-0.59	0.86	0.39	-0.65	-0.09		-0.08	-0.78	0.68	-0.54	-0.14	0.24	-0.62	-0.17	0.78	-0.66	0.76	-0.52	-0.02	0.07	0.74	0.65
Non Currrent Assets Other	0.07	0.27	-0.24	0.18	-0.02	0.17	0.36	0.02	-0.38	-0.08		-0.04	0.22	0.05	-0.03	0.27	-0.39	-0.24	0.18	0.08	0.22	0.05	-0.16	-0.25	-0.06	0.13
Cash And Short Term Investments	0.77	-0.49	0.4	-0.38	0.82	-0.72	-0.33	0.91	0.09	-0.78	-0.04		-0.78	0.66	-0.01	-0.71	0.79	-0.02	-0.58	0.8	-0.66	0.64	0.15	-0.23	-0.94	-0.61
Net Receivables	-0.47	0.82	-0.46	0.49	-0.69	0.89	0.78	-0.68	-0.54	0.68	0.22	-0.78		-0.43	0.18	0.46	-0.72	0.08	0.8	-0.59	0.89	-0.41	-0.62	-0.02	0.56	0.83
Common Stock Shares Outstanding	0.2	-0.08	0.05	-0.07	0.16	-0.42	-0.03	0.58	-0.03	-0.54	0.05	0.66	-0.43		0.05	-0.29	0.68	-0.15	-0.25	0.14	-0.3	1.0	-0.02	-0.36	-0.61	-0.36
Non Current Liabilities Total	-0.14	0.34	-0.74	-0.56	-0.2	0.09	0.41	-0.2	-0.38	-0.14	-0.03	-0.01	0.18	0.05		-0.13	-0.07	0.23	0.18	-0.04	0.11	0.05	-0.5	-0.09	-0.1	0.29
Inventory	-0.78	0.12	-0.17	0.16	-0.67	0.22	0.1	-0.64	-0.04	0.24	0.27	-0.71	0.46	-0.29	-0.13		-0.55	0.11	0.12	-0.63	0.26	-0.27	-0.02	0.16	0.68	0.21
Other Current Assets	0.51	-0.43	0.32	-0.29	0.58	-0.68	-0.39	0.69	0.27	-0.62	-0.39	0.79	-0.72	0.68	-0.07	-0.55		-0.02	-0.53	0.52	-0.56	0.65	0.2	-0.21	-0.64	-0.61
Other Stockholder Equity	-0.06	-0.2	0.05	-0.32	0.03	-0.13	-0.16	-0.09	0.11	-0.17	-0.24	-0.02	0.08	-0.15	0.23	0.11	-0.02		-0.15	0.08	-0.19	-0.14	-0.05	0.38	-0.01	-0.11
Total Liab	-0.22	0.94	-0.51	0.69	-0.59	0.93	0.75	-0.49	-0.37	0.78	0.18	-0.58	0.8	-0.25	0.18	0.12	-0.53	-0.15		-0.51	0.96	-0.23	-0.39	-0.09	0.44	0.65
Total Current Assets	0.9	-0.47	0.4	-0.41	0.96	-0.58	-0.26	0.76	-0.02	-0.66	0.08	0.8	-0.59	0.14	-0.04	-0.63	0.52	0.08	-0.51		-0.55	0.1	0.08	-0.17	-0.8	-0.45
Short Term Debt	-0.31	0.94	-0.45	0.7	-0.63	0.95	0.8	-0.56	-0.45	0.76	0.22	-0.66	0.89	-0.3	0.11	0.26	-0.56	-0.19	0.96	-0.55		-0.29	-0.51	-0.09	0.5	0.72
Common Stock	0.17	-0.07	0.05	-0.05	0.12	-0.41	-0.02	0.56	-0.03	-0.52	0.05	0.64	-0.41	1.0	0.05	-0.27	0.65	-0.14	-0.23	0.1	-0.29		-0.01	-0.35	-0.58	-0.35
Accounts Payable	0.09	-0.61	0.32	0.03	0.24	-0.46	-0.81	0.23	0.79	-0.02	-0.16	0.15	-0.62	-0.02	-0.5	-0.02	0.2	-0.05	-0.39	0.08	-0.51	-0.01		0.1	0.15	-0.64
Current Deferred Revenue	-0.31	-0.25	0.36	-0.07	-0.18	0.04	-0.39	-0.38	0.52	0.07	-0.25	-0.23	-0.02	-0.36	-0.09	0.16	-0.21	0.38	-0.09	-0.17	-0.09	-0.35	0.1		0.28	-0.28
Good Will	-0.78	0.3	-0.33	0.36	-0.77	0.55	0.05	-0.85	0.22	0.74	-0.06	-0.94	0.56	-0.61	-0.1	0.68	-0.64	-0.01	0.44	-0.8	0.5	-0.58	0.15	0.28		0.36
Other Liab	-0.29	0.72	-0.55	0.29	-0.48	0.79	0.81	-0.57	-0.75	0.65	0.13	-0.61	0.83	-0.36	0.29	0.21	-0.61	-0.11	0.65	-0.45	0.72	-0.35	-0.64	-0.28	0.36

Click cells to compare fundamentals

Jagsonpal Pharmaceuticals Account Relationship Matchups

Jagsonpal Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.5B	1.6B	1.7B	1.9B	2.2B	1.7B
Short Long Term Debt Total	37.9M	46.6M	67.9M	60.0M	89.4M	165.5M
Other Current Liab	155.5M	117.4M	4.6M	183.3M	88.5M	78.7M
Total Current Liabilities	328.3M	404.0M	341.6M	275.7M	191.3M	361.4M
Total Stockholder Equity	1.1B	1.2B	1.3B	1.6B	1.9B	1.2B
Property Plant And Equipment Net	239.6M	233.5M	223.7M	242.8M	93.0M	88.4M
Net Debt	(334.1M)	(518.4M)	(251.4M)	(50.5M)	(38.2M)	(36.3M)
Retained Earnings	476.9M	585.9M	675.2M	945.4M	1.0B	1.1B
Cash	380.7M	586.3M	251.4M	110.5M	127.6M	199.6M
Non Current Assets Total	520.4M	437.3M	576.8M	303.9M	178.2M	169.3M
Non Currrent Assets Other	(353.8M)	38.3M	29.2M	27.2M	38.2M	40.1M
Cash And Short Term Investments	380.7M	618.8M	472.8M	1.1B	1.5B	1.6B
Net Receivables	224.5M	126.6M	155.8M	221.1M	109.5M	104.0M
Liabilities And Stockholders Equity	1.5B	1.6B	1.7B	1.9B	2.2B	1.7B
Non Current Liabilities Total	30.9M	18.8M	34.4M	84.8M	105.5M	87.4M
Inventory	293.3M	297.2M	297.4M	206.8M	150.0M	247.3M
Other Current Assets	274.5M	143.6M	80.6M	41.9M	363.2M	381.4M
Total Liab	359.2M	422.7M	376.0M	360.6M	296.8M	350.2M
Total Current Assets	949.1M	1.2B	1.1B	1.6B	2.0B	1.1B
Accumulated Other Comprehensive Income	(337.4M)	1.1B	496.9M	506.5M	588.7M	618.2M
Short Term Debt	64.0M	67.9M	7.5M	7.5M	13.8M	13.1M
Accounts Payable	117.1M	180.5M	185.5M	78.5M	76.0M	96.0M
Current Deferred Revenue	92.1M	137.5M	(7.5M)	81.4M	12.9M	12.3M
Other Liab	30.9M	18.8M	34.4M	32.4M	29.1M	26.0M
Net Tangible Assets	1.1B	1.2B	1.3B	1.6B	1.8B	1.2B
Other Assets	170.1M	82.9M	147.0M	20.3M	23.4M	22.2M
Property Plant Equipment	239.6M	233.5M	223.7M	242.8M	218.5M	258.8M
Cash And Equivalents	398.1M	589.4M	232.3M	110.5M	127.1M	242.0M
Net Invested Capital	1.2B	1.3B	1.3B	1.6B	1.9B	1.5B
Net Working Capital	620.8M	800.8M	766.2M	1.4B	1.8B	1.1B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Other Information on Investing in Jagsonpal Stock

Balance Sheet is a snapshot of the financial position of Jagsonpal Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Jagsonpal Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jagsonpal Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jagsonpal currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jagsonpal Common Stock Shares Outstanding vs Cash And Short Term Investments Analysis

Common Stock Shares Outstanding vs Cash And Short Term Investments

Common Stock Shares Outstanding vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Cash And Short Term Investments

Jagsonpal Pharmaceuticals fundamental ratios Correlations

Jagsonpal Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jagsonpal Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Jagsonpal Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Shares Outstanding
Total Current Assets	+ 0.96	Total Stockholder Equity
Short Term Debt	+ 0.96	Total Liab
Short Term Debt	+ 0.95	Property Plant And Equipment Net
Total Liab	+ 0.94	Short Long Term Debt Total
Short Term Debt	+ 0.94	Short Long Term Debt Total

Good Will	- 0.94	Cash And Short Term Investments
Cash	- 0.87	Net Debt
Good Will	- 0.85	Retained Earnings
Accounts Payable	- 0.81	Net Debt
Good Will	- 0.8	Total Current Assets
Net Receivables	- 0.78	Cash And Short Term Investments